Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients
What is the GEM-CESAR trial?
The GEM-CESAR trial is a potentially curative strategy for high-risk smoldering multiple myeloma (HRsMM) patients (pts) in which the primary endpoint is the achievement of sustained minimal residual disease (MRD) negativity in the bone marrow (BM) by next generation flow (NGF). The value of bone marrow MRD assessment in multiple myeloma is proven, but alternative, non-invasive methods, accurately reflecting disease burden are needed.
In this video:
Dr. Noemi Puig (University of Salamanca — Salamanca, Spain) explains that the GEM-CESAR treatment strategy induces a high overall response rate in high-risk smoldering multiple myeloma patients, and the percentage of cases achieving flow-minimal residual disease (MRD) negativity after autologous stem cell transplant meets the primary endpoint of the trial.
The combined use of QIP-MS and FLC-MS offers higher sensitivity relative to standard methods and may provide relevant information about the right timing for performing a BM aspirate/biopsy.
Clinical trial information: NCT02415413.
NOEMI PUIG, MD
Noemi Puig, MD, PhD earned her medical degree from the Universidad Complutense in Madrid and she completed her residency in Internal Medicine and Hematology at the University Hospital La Fe in Valencia,Spain. She completed a 3-year fellowship in Lymphoma, Myeloma and Autologous Stem Cell Transplantation at the Princess Margaret Hospital in the University of Toronto, in Toronto, Canada. She earned a doctoral degree at the Medicine Department of the University of Salamanca, in Spain, with a thesis entitled “Optimization and Critical Analysis of Minimal Residual Disease Monitoring with ASO RQ-PCR in Patients with Multiple Myeloma and Comparison with Multiparameter Flow Cytometry.” Dr. Puig currently serves as a Consultant Physician at the Hematology Department in the University Hospital of Salamanca. She also works in the Flow Cytometry Laboratory of the University Hospital of Salamanca, where she is responsible for the studies developed by the Spanish Myeloma Group.
Dr. Puig is a member of the Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA)and the Spanish Myeloma Group (GEM) as well as of the EuroFlow Group.